Rohit Aggarwal, Hector Chinoy, Ingrid E. Lundberg, Masataka Kuwana, Ruth Ann Vleugels, Consuelo Anzilotti et al. A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial. // ACR Open Rheumatology. – 2026. – DOI: 10.1002/acr2.90155. – URL: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.90155?af=R
Rohit Aggarwal, Hector Chinoy, Ingrid E. Lundberg, Masataka Kuwana, Ruth Ann Vleugels, Consuelo Anzilotti, Andrew Beaton, Celeste Cummings, Tina Luu, & Maroua Benghoul (2026). A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial. ACR Open Rheumatology. https://doi.org/10.1002/acr2.90155
Rohit Aggarwal, et al. “A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial.” ACR Open Rheumatology, 2026. doi:10.1002/acr2.90155.
@article{Aggarwal2026,
title = {A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial},
author = {Aggarwal, Rohit and Chinoy, Hector and Lundberg, Ingrid E. and Kuwana, Masataka and Vleugels, Ruth Ann and Anzilotti, Consuelo and Beaton, Andrew and Cummings, Celeste and Luu, Tina and Benghoul, Maroua},
journal = {ACR Open Rheumatology},
year = {2026},
doi = {10.1002/acr2.90155},
url = {https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.90155?af=R}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...